ClinicalTrials.Veeva

Menu

Screening and Understanding of the Pre-diabetes: DECODIAB

N

Nantes University Hospital (NUH)

Status

Unknown

Conditions

Pre-diabetes

Treatments

Other: Biopsies of muscular and fat tissue

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The main objective of the study is to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in the population of patients with pre-diabetes.

Enrollment

103 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients (≥18 years)
  • Subjects with diabetes risk score ≥ 12 or with impaired fasting glucose: blood glucose ≥ 1.10 g/l and < 1 .26 g/L
  • And with impaired fasting glucose : blood glucose ≥ 1.10 g/l and < 1 .26 g/L ; or blood glucose ≥ 1g/l and < 1,1 g/L WITH HbA1C ≥ 6,5%
  • Signed informed consent
  • Subjects affiliated with an appropriate social security system

Exclusion criteria

  • Fasting glycemia ≥ 1.26 g/l
  • Fasting glycemia ≤ 1.10 g/l AND HbA1C < 6,5%
  • Fasting glycemia < 1 g/l
  • Subjects previously treated with oral anti-diabetic: metformin, glitazones, inhibitors of α-glucosidase, sulfonylurea, repaglinide, inhibitors of DPP-IV.
  • Subjects previously treated with insulin, except gestational diabetes
  • Severe coagulation disorders
  • Thrombocytopenia < 100 000/mm 3
  • Severe psychiatric disorders
  • Severe renal insufficiency (creatinine clearance < 30 ml/min)
  • Severe hepatic insufficiency
  • Alcohol abuse (> 30g/j)
  • Contra-indication in the realization of the local anesthetic
  • Subject unable to follow the study during the 5 years of follow-up
  • Subject exclusion period in a previous study

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems